Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vapendavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Altesa Secures IND Clearance for Vapendavir Development
Details : Vapendavir is a broad-spectrum antiviral medicine that prevents the virus from entering human cells and reproducing. It is being studied for rhinovirus infections in people with COPD.
Product Name : BTA798
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2025
Lead Product(s) : Vapendavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALT-2023
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Drug Innovation Ventures at Emory
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration includes a license to ALT-2023, a broadly active nucleoside analogue that is late stage preclinical development, as well as options to additional compounds addressing RNA viruses.
Product Name : ALT-2023
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 02, 2022
Lead Product(s) : ALT-2023
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Drug Innovation Ventures at Emory
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Vapendavir
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Altesa BioSciences to Initiate Clinical Trials of Promising Antiviral
Details : BTA798 (Vapendavir) has shown promising preclinical and clinical data demonstrating effective control of certain respiratory viruses, can potentially be used to treat epidemic hand, foot and mouth disease (HFMD) and HRV infection in COPD Patients.
Product Name : BTA798
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Vapendavir
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : National Institutes of Health
Deal Size : $52.0 million
Deal Type : Funding
Details : With the newly announced AViDD award, Altesa options include relevant compounds advanced by DRIVE stemming from Emory’s Antiviral Countermeasure Development Center.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 25, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : National Institutes of Health
Deal Size : $52.0 million
Deal Type : Funding